Russian drugmaker Polysan will invest about 4 billion roubles (~$60 million) in the establishment of… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (generics, biosimilars, coronavirus/COVID-19, digital pharma, Asia Pacific), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Russian pharmaceutical producer Polysan will invest about RUB4bn ($60m) in the full-cycle production of German drug firm Bayer's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 7 day on the production of Gadovist, Magnevist and Ultravist at Polysan's St Petersburg facility. The latest collaboration will also see Polysan's antiviral treatment Cytoflavin manufactured at the plant.